Please login to the form below

Not currently logged in
Email:
Password:

Bamboo Therapeutics

This page shows the latest Bamboo Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Bayer pays an initial $2bn for gene therapy firm AskBio

Bayer pays an initial $2bn for gene therapy firm AskBio

Samulski also created two AskBio subsidiaries, Bamboo Therapeutics and Chatham Therapeutics, which focused on Duchenne muscular dystrophy and haemophilia respectively. ... In 2016, Pfizer acquired Bamboo, providing it with a leading gene therapy for

Latest news

  • Pfizer goes big on gene therapy with $500m facility spend Pfizer goes big on gene therapy with $500m facility spend

    Pfizer also added to its stable with the $700m acquisition of gene therapy specialist  Bamboo Therapeutics, which added an rAAV platform as well as candidates for giant axonal neuropathy and Duchenne ... It also took a 15% stake in  Vivet Therapeutics

  • Catalent preps for complex therapy boom with $1.2bn Paragon buy Catalent preps for complex therapy boom with $1.2bn Paragon buy

    Last month, Pfizer paid around $640m for a 15% stake in Vivet Therapeutics, while Biogen snapped up Nightstar Therapeutics for $800m and Roche acquired Spark Therapeutics in February for $4.3bn. ... And in 2018, Novartis’ bought AveXis for $8.7bn to

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics ... Pfizer still has an iron in the DMD fire, in the form of its Bamboo

  • Pfizer buys gene therapy specialist Bamboo Pfizer buys gene therapy specialist Bamboo

    Pfizer has made a play for a larger chunk of the emerging gene therapy market, agreeing a $700m deal to acquire Bamboo Therapeutics. ... Another $495m will go to Bamboo's investors if its gene therapy programmes make it through development and onto the

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    $14bn, antibiotic business interests from AstraZeneca for $1.4bn and Bamboo Therapeutics for $645m. ... 690. Bamboo Therapeutics (US). Pfizer (US). Company acquisition. Preclinical gene therapies and manufacturing plant.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....